No patients were harmed in the trial and patients in both groups lived longer than expected, with those being given lintuzumab having a lower death rate.
In the study, no participants suffered any adverse effects, and people in both groups outlived their expected lifespans. Those administered lintuzumab had a lower mortality rate.